AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Putative RNA polymerase II subunit B1 CTD phosphatase RPAP2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8IXW5

UPID:

RPAP2_HUMAN

Alternative names:

RNA polymerase II-associated protein 2

Alternative UPACC:

Q8IXW5; C9JKB5; Q49AS7; Q9H8Y2

Background:

The Putative RNA polymerase II subunit B1 CTD phosphatase RPAP2, also known as RNA polymerase II-associated protein 2, plays a crucial role in the transcription regulation of snRNA genes. It specifically targets the CTD of POLR2A, facilitating transcription by dephosphorylating 'Ser-5'. Additionally, RPAP2 is involved in the endoplasmic reticulum unfolded protein response by dephosphorylating ERN1, thus influencing apoptosis.

Therapeutic significance:

Understanding the role of Putative RNA polymerase II subunit B1 CTD phosphatase RPAP2 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.